Sherene Loi
Associate Professor
Medicine
Peter MacCallum Cancer Centre
Australia
Biography
As head of the Translational Breast Cancer Genomics Laboratory, Associate Professor Sherene Loi's research interest is to translate interesting scientific findings into innovative treatment approaches that may ultimately improve the clinical outcomes of breast cancer patients. To facilitate this, her laboratory uses genomic approaches to analyse breast cancer specimens to understand mechanisms of growth, immune evasion and progression. For patients, Assoc. Prof. Loi's interest lies in clinical trials evaluating targeted agents against specific breast cancer molecular subtypes.
Research Interest
Breast Cancer Genomics
Publications
-
Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions. Wein L, Savas P, Luen SJ, Virassamy B, Salgado R, Loi S. Front Oncol. 2017 Aug 3;7:156. doi: 10.3389/fonc.2017.00156.
-
Neoadjuvant Interferons: Critical for effective PD-1 based immunotherapy in TNBC. Brockwell NK, Owen KL, Zanker D, Spurling A, Rautela J, Duivenvoorden HM, Baschuk N, Caramia F, Loi S, Darcy PK, Lim E, Parker BS. Cancer Immunol Res. 2017 Aug 28. pii: canimm.0150.2017.
-
CD73 promotes resistance to HER2/ErbB2 antibody therapy. Turcotte M, Allard D, Mittal D, Bareche Y, Buisseret L, Jose V, Pommey S, Delisle V, Loi S, Joensuu H, Kellokumpu-Lehtinen PL, Sotiriou C, Smyth MJ, Stagg J. Cancer Res. 2017
